DUBLIN--(http://www.researchandmarkets.com/research/9qnflm/systemic_lupus) has announced the addition of Decision Resources, Inc's new report "Systemic Lupus Erythematosus (Event Driven)" to their offering.)--Research and Markets (
In the past, systemic lupus erythematosus (SLE) drug developers faced formidable challenges: drug development and regulatory hurdles, a small and heterogeneous population, and the multiplicity of manifestations all contribute to these challenges.
Recent positive clinical trial results and regulatory approval of the first agent in 50 years will ease some of the drug development hurdles and usher in a new era of SLE drug development. We forecast that sales of SLE therapies will increase more than five-fold over our 2010-2020 forecast period, driven largely by the entry and uptake of premium-priced biologics.
The SLE market also reflects an unusual dynamicthe continued off-label use of several therapies that have failed clinical trialsfurther underscoring the high unmet need and opportunity in this indication.
Key Topics Covered:
1 Etiology and Pathophysiology
2 Epidemiology and Patient Populations
3 Current Therapies and Medical Practice
4 Unmet Needs
5 Emerging Therapies
6 Market Outlook
Tables and Figures
For more information visit http://www.researchandmarkets.com/research/9qnflm/systemic_lupus
Source: Decision Resources, Inc